Drug Type Trispecific killer cell engager (TriKE) |
Synonyms |
Target |
Mechanism CD16a antagonists(Low affinity immunoglobulin gamma Fc region receptor III-A antagonists), CD47 inhibitors(Cluster of differentiation 47 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 13 Mar 2023 |